Enlivex Therapeutics
1D
1W
1M
3M
YTD
1Y
5Y
ALL
Why Robinhood?
Robinhood gives you the tools you need to put your money in motion. You can buy or sell ENLV and other ETFs, options, and stocks.About ENLV
Enlivex Therapeutics Ltd. engages in the development of macrophage reprogramming immunotherapy products. It focuses on the development of Allocetra, a universal off-the-shelf cell therapy designed to reprogram macrophages into their homeostatic state.
CEOOren Hershkovitz
CEOOren Hershkovitz
Employees36
Employees36
HeadquartersNess Ziona, Tel Aviv
HeadquartersNess Ziona, Tel Aviv
Founded2012
Founded2012
Employees36
Employees36
ENLV Key Statistics
Market cap23.82M
Market cap23.82M
Price-Earnings ratio-1.77
Price-Earnings ratio-1.77
Dividend yield—
Dividend yield—
Average volume144.25K
Average volume144.25K
High today$1.02
High today$1.02
Low today$0.98
Low today$0.98
Open price$1.02
Open price$1.02
Volume177.51K
Volume177.51K
52 Week high$2.10
52 Week high$2.10
52 Week low$0.8101
52 Week low$0.8101
Stock Snapshot
As of today, Enlivex Therapeutics(ENLV) shares are valued at $1.00. The company's market cap stands at 23.82M, with a P/E ratio of -1.77.
On 2025-11-06, Enlivex Therapeutics(ENLV) stock moved within a range of $0.98 to $1.02. With shares now at $1.00, the stock is trading +2.0% above its intraday low and -2.0% below the session's peak.
Trading volume for Enlivex Therapeutics(ENLV) stock has reached 177.51K, versus its average volume of 144.25K.
The stock's 52-week range extends from a low of $0.81 to a high of $2.10.
The stock's 52-week range extends from a low of $0.81 to a high of $2.10.
People also own
Based on the portfolios of people who own ENLV. This list is generated using Robinhood data, and it’s not a recommendation.